10-(6,6-dimethoxyethyl)-4,6,8-trihydroxy-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one | 870702-57-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 10-(6,6-dimethoxyethyl)-4,6,8-trihydroxy-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one
• 英文别名: 5-(2,2-dimethoxyethyl)-1,3,10-trihydroxy-11H-benzo[b][1,4]benzodiazepin-6-one
• CAS: 870702-57-1
• 化学式: C₁₇H₁₈N₂O₆
• 分子量: 346.34
• InChiKey: SQBXTUXHTLCMHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  112
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  甲醇 、 diazepinomicin 在 臭氧 、 二甲基硫 作用下， 反应 24.03h， 生成 10-(6,6-dimethoxyethyl)-4,6,8-trihydroxy-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one 、 10-(6,6-dimethoxy-3-methyl-2-hexenyl)-4,6,8-trihydroxy-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one
  参考文献：
  名称：

  TUMOR-TARGETING EVALUATION METHODOLOGY AND COMPOUNDS RELATED THERETO

  摘要：

  该发明涉及一种评估候选分子化疗潜力的方法。在评估候选分子时，将测试候选分子抑制癌细胞体外生长的能力；结合由癌细胞产生的细胞受体，其中所述受体，如外周苯二氮卓受体，由所述癌细胞产生的数量比正常细胞多；并抑制MAPK通路中至少一个蛋白质成员的活性。该发明还涉及二苯二氮卓酮类似物及其衍生物。

  公开号：

  US20090062255A1

文献信息

• DIBENZODIAZEPINONE ANALOGUES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS
  申请人：McAlpine James B.

  公开号：US20080161291A1

  公开（公告）日：2008-07-03

  The invention relates to biologically active dibenzodiazepinone analogs represented by Formula I, to methods of producing them, to pharmaceutical compositions comprising them and to methods of treating neoplastic conditions.
• METHODS FOR TREATING RAS DRIVEN CANCER IN A SUBJECT
  申请人：GOURDEAU Henriette

  公开号：US20090170837A1

  公开（公告）日：2009-07-02

  The invention relates to the discovery that the dibenzodiazepinone analogues have growth inhibiting activities on tumorigenic cells that are driven by expression of RAS or mutated RAS. Thus the invention includes methods for inhibiting the activity of RAS using dibenzodiazepinone analogues; methods for inhibiting the growth of a RAS driven cancer cell using dibenzodiazepinone analogues; methods for inhibiting the growth of a RAS driven cancer using dibenzodiazepinone analogues; and methods for treating a subject having a RAS driven cancer using dibenzodiazepinone analogues.
• US7304054B2
  申请人：——

  公开号：US7304054B2

  公开（公告）日：2007-12-04
• US7655646B2
  申请人：——

  公开号：US7655646B2

  公开（公告）日：2010-02-02
• [EN] INHIBITION OF CELL MIGRATION BY A FARNESYLATED DIBENZODIAZEPINONE<br/>[FR] INHIBITION DE LA MIGRATION CELLULAIRE PAR UNE DIBENZODIAZÉPINONE FARNÉSYLÉE
  申请人：THALLION PHARMACEUTICALS INC

  公开号：WO2009124399A1

  公开（公告）日：2009-10-15

  The invention relates to the discovery that dibenzodiazepinone analogues have cell migration inhibiting activities on neoplastic and endothelial cells. The migration of neoplastic cells from various tumor types, such as a glioma tumor that may comprise an EGF and/or PTEN mutation, or a Ras-, Raf, or EGFR-mediated tumor, may be inhibited when contacted by the dibenzodiazepinone analogues of the present invention. The invention includes methods for inhibiting migration of a cell in a subject, by contacting a cell with a dibenzodiazepinone analogue of the present invention.